Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Abroad (travel likely)RecruitingPHASE1

Conditions

Locally Advanced Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma · Solid Tumor · Metastatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California San Francisco (UCSF), San Francisco, California, United States
Contact: Study coordinator (Quincy Harris) · 415-502-3310
Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Haley Ellis, MD) · 617-724-4000
The Ohio State University, Columbus, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Jodi Rodon Ahnert, MD) · 713-792-5603

Study leads

Doug Warner
Study Chair
Tyra Biosciences, Inc

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Cholangiocarcinoma

Abroad (travel likely)Recruiting

Bad Liebenwerda, Germany · Bad Mergentheim, Germany

Evaluation of Skin Tests in Biotherapy Allergies

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck · Melanoma Neoplasms · Small Cell Bronchial Carcinomas

Abroad (travel likely)Recruiting

Angers, France

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Bile Duct Cancer · Cholangiocarcinoma · Cholangiocarcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Boston, United States

PULSAR Combined With Immunotherapy and Chemotherapy

Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China